FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management


Volume 225


Reference List

Reference 1 - Brachman, P. S.; H. Gold; S. A. Plotkin; F. R. Fekety; M. Werrin; and N. R. Ingraham, “Field Evaluation of a Human Anthrax Vaccine,” American Journal of Public Health, 52: 632-645, 1962. Published Material

Reference 2 - Institute of Medicine. “The Anthrax Vaccine. Is It Safe? Does It Work?” Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-Up Agency. Washington, DC: National Academy Press, 2002. Published Material

Reference 3 - Fellows, P. F.; M. K. Linscott; B. E. Ivins; M. L. M. Pitt; C. A. Rossi; P. H. Gibbs and A. M. Friedlander, “Efficacy of a Human Anthrax Vaccine in Guinea Pigs, Rabbits, and Rhesus Macaques Against Challenge by Bacillus Anthracis Isolates of Diverse Geographical Origin,” Vaccine 19(23/24): 3241-3247, 2001. Published Material

Reference 4 - Ivins, B. E.; P. F. Fellows; M. L. M. Pitt; J. E. Estep; S. L. Welkos; P. L.Worsham and A. M. Friedlander, “Efficacy of a Standard Human Anthrax Vaccine Against Bacillus Anthracis Aerosol Spore Challenge in Rhesus Monkeys,” Salisbury Medical Bulletin 87(Suppl.): 125-126, 1996. Published Material

Reference 5 - Ivins, B. E.; M. L. M. Pitt; P. F. Fellows; J. W. Farchaus; G. E. Benner; D. M. Waag; S. F. Little; G. W. Anderson, Jr.; P. H. Gibbs; and A. M. Friedlander, “Comparative Efficacy of Experimental Anthrax Vaccine Candidates Against Inhalation Anthrax in Rhesus Macaques,” Vaccine, 16(11/12): 1141-1148, 1998. Published Material

Reference 6 - Anthrax Vaccine Adsorbed (BIOTHRAX) Package Insert (January 31, 2002).

Reference 7 - Wright, G. G.; T. W. Green; and R.G. Kanode, Jr., “Studies on Immunity in Anthrax: V. Immunizing Activity of Alum-Precipitated Protective Antigen,” Journal of Immunologv, 73: 387-391, 1954.

Reference 8 - “FDA Guidance Concerning Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products,” April 1996.

Reference 9 - “Revocation of Certain Regulations; Biological Products,” Final Rule; 61 FR 40153, August 1, 1996.

Reference 10 - “International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials,” Notice of Availability; 63 FR 49583, September 16, 1998.

Reference 11 - Plotkin, S. A., P.S. Brachman, M. Utell, F. H. Bumford, and M. M. Atchinson, “An Epidemic of Inhalation Anthrax, the First in the Twentieth Century, I. Clinical Features.” American Journal of Medicine, 29: 992-1001, 1960. Published Material

Reference 12 - Brachman, P.S., S. A. Plotkin, F. H. Bumford, and M. M. Atchinson, “An Epidemic of Inhalation Anthrax: The First in the Twentieth Century, II. Epidemiology.” American Journal of Hygiene; 72: 6-23, 1960. Published Material

Reference 13 - Pittman, P. R.., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander, “Anthrax Vaccine: Immunogenicity and Safety of a Dose-Reduction, Route-Change Comparison Study in Humans,” Vaccine; 20(9-10): 1412-1420, 2002. Published Material

Reference 14 - “Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment,” March 2005.

Reference 15 - Institute of Medicine. “Adverse Effects of Pertussis and Rubella Vaccines.” A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press, 1991. Published Material

Reference 16 - Institute of Medicine. “Immunization Safety Review.” http://www.iom.edu/project.asp?id=4705 Published Material

Reference 17 - Review of VAERS Anthrax Vaccine Reports Received Through 8/15/05, and Adverse Event Reports Submitted to Docket No. 1980N-0208; dated December 2005.

Reference 18 - Puziss, M., L. C. Manning, J. W. Lynch, E. Barclay, I. Abelow, and G. G. Wright, “Large-Scale Production of Protective Antigen of Bacillus anthracis in Anaerobic Cultures.” Applied Microbiology, 11(4): 330-334, 1963. Published Material

Reference 19 - Wright, G. G.., M. Puziss, and W. B. Neely, “Studies on Immunity in Anthrax, IX. Effect of Variations in Cultural Conditions on Elaboration of Protective Antigen by Strains of Bacillus anthracis.” Journal of Bacteriology, 83: 515-522, 1962. Published Material

Reference 20 - Nikkila K., K. Hiickerstedt, and T. A. Miettinen, “Serum and Hepatic Cholestanol, Squalene and Noncholesterol Sterols in Man: A Study on Liver Transplantation,” Hepatoloay, 15: 863-70, 1992. Published Material

Reference 21 - Matyas, G. F:., M. Rao, P. R. Pittman, R. Burge, I. E. Robbins, N. M. Wassef, B. Thivierge, and C. R. Alving, “Detection of Antibodies to Squalene III. Naturally Occurring Antibodies to Squalene in Humans and Mice,” Journal of Immunological Methods, 286: 47-67, 2004. Published Material

Reference 22 - Jernigan, J. A., et al., “Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States,” Emerging Infectious Diseases, 7(6):933-944, 2001. Published Material

Reference 23 - Barakat, L. A., et al., “Fatal Inhalational Anthrax in a 94-Year-Old Connecticut Woman,” Journal of the American Medical Association, 287(7): 863-868, 2002. Published Material

Top | Back

Page last updated December 28, 2005 RSChorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management